公开(公告)号：EP2477739B1

公开(公告)日：2019-04-10

申请号：EP10750127.2

申请日：2010-09-09

Applicant: BASF SE

Inventor： HINTERMANN, Tobias ,  BAUER, Didier ,  CARROY, Antoine ,  LORDELOT, Caroline ,  KOHLI STECK, Rachel

IPC: B01J31/02 ,  B01J31/22 ,  C08G18/22 ,  C08G18/62 ,  C08G18/79 ,  C09D175/04

公开(公告)号：EP2861589B1

公开(公告)日：2017-05-17

申请号：EP13804937.4

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO, Tiziana ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  SZELAGIEWICZ, Martin ,  BLATTER, Fritz ,  SIEBENHAAR, Bernd ,  VOSSEN, Marcus

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/02

CPC classification number: C07D417/12 ,  A61K31/506 ,  C07B2200/07 ,  C07B2200/13 ,  C07C35/12 ,  C07C47/58 ,  C07C65/03 ,  C07C69/84 ,  C07D213/82 ,  C07D309/40 ,  A61K2300/00

公开(公告)号：EP3160963A1

公开(公告)日：2017-05-03

申请号：EP15731329.7

申请日：2015-06-24

Applicant: BASF SE

Inventor： VIERTELHAUS, Martin ,  CHIODO, Tiziana ,  SALVADOR, Beate ,  VOSSEN, Marcus ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SZELAGIEWICZ, Martin ,  BLATTER, Fritz

IPC: C07D417/12 ,  A61K31/506

CPC classification number: C07D417/12

Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.

Abstract translation: 本发明主要涉及包含式1化合物和选自薄荷醇和香草醛的第二化合物的多组分晶体。 本发明还涉及包含这种多组分晶体的药物组合物。 此外，本发明涉及制备所述多组分晶体的方法。 本发明还涉及使用所述多组分晶体或药物组合物治疗疾病的几个方面。

公开(公告)号：EP3080141A1

公开(公告)日：2016-10-19

申请号：EP14809636.5

申请日：2014-12-09

Applicant: BASF SE

Inventor： CHIODO, Tiziana ,  SALVADOR, Beate ,  VOSSEN, Marcus ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SZELAGIEWICZ, Martin ,  BLATTER, Fritz ,  VIERTELHAUS, Martin ,  WEISHAAR, Walter

IPC: C07J43/00 ,  A61K9/14 ,  A61K31/58 ,  A61P35/00

CPC classification number: A61K31/58 ,  A61K9/14 ,  C07B2200/13 ,  C07J43/003

Abstract: Combinations of (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

公开(公告)号：EP3024831A2

公开(公告)日：2016-06-01

申请号：EP14741880.0

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER, Andreas ,  BLATTER, Fritz ,  SZELAGIEWICZ, Martin ,  SIEBENHAAR, Bernd ,  CHIODO, Tiziana ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  VOSSEN, Marcus

IPC: C07D417/12

CPC classification number: C07D417/12 ,  C07C55/12 ,  C07D213/80 ,  C07D275/06

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract translation: 本发明主要涉及达沙替尼的盐，其中盐是无定形形式。 本文所述的盐优选包含式1的化合物的阳离子和选自戊二酸，烟酸和糖精的第二化合物的阴离子。 本发明进一步涉及包含这种盐的药物组合物。 此外，本发明涉及制备所述盐的方法。 本发明还涉及使用所述盐或药物组合物治疗疾病的几个方面。

公开(公告)号：EP2861589A2

公开(公告)日：2015-04-22

申请号：EP13804937.4

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO, Tiziana ,  HAFNER, Andreas ,  HINTERMANN, Tobias ,  SALVADOR, Beate ,  SZELAGIEWICZ, Martin ,  BLATTER, Fritz ,  SIEBENHAAR, Bernd ,  VOSSEN, Marcus

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D417/12 ,  A61K31/506 ,  C07B2200/07 ,  C07B2200/13 ,  C07C35/12 ,  C07C47/58 ,  C07C65/03 ,  C07C69/84 ,  C07D213/82 ,  C07D309/40 ,  A61K2300/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.

公开(公告)号：EP2477738A1

公开(公告)日：2012-07-25

申请号：EP10747638.4

申请日：2010-09-01

Applicant: BASF SE

Inventor： HINTERMANN, Tobias ,  BAUER, Didier ,  CARROY, Antoine ,  LORDELOT, Caroline ,  KOHLI STECK, Rachel

IPC: B01J31/02 ,  B01J31/22 ,  C08G18/22

CPC classification number: B01J31/2234 ,  B01J31/0214 ,  B01J31/223 ,  B01J2231/34 ,  B01J2531/46 ,  B33Y70/00 ,  C08G18/222 ,  C08G18/6229 ,  C08G18/792 ,  C09D175/04

Abstract: The present invention provides photolatent Ti-chelate catalyst compounds of formula (I), wherein R1 is for example C6-C14 aryl which is substituted by one or more R′2, R′3 or R′4; or the two R1 together are unsubstituted linear or branched C1-C12alkylene; R2, R3, R4, R′2, R′3, and R′4 independently of each other are for example hydrogen, halogen or linear or branched C1-C20alkyl; R5, R6 and R7 independently of each other are hydrogen, linear or branched C1-C20alkyl, C6-C14aryl, Br or Cl, provided that not more than one of R5, R6 and R7 is hydrogen; as well as formulations comprising said compounds and defined 1,3-diketones.

Abstract translation: 本发明提供式（I）的光催化钛螯合催化剂化合物，其中R 1为例如被一个或多个R'2，R'3或R'4取代的C 6 -C 14芳基; 或两个R 1一起是未取代的直链或支链C 1 -C 12亚烷基; R 2，R 3，R 4，R'2，R'3和R 4彼此独立地是例如氢，卤素或直链或支链C 1 -C 20烷基; R 5，R 6和R 7彼此独立地是氢，直链或支链C 1 -C 20烷基，C 6 -C 14芳基，Br或Cl，条件是不多于一个R 5，R 6和R 7是氢; 以及包含所述化合物和所定义的1,3-二酮的制剂。

公开(公告)号：EP1397349B1

公开(公告)日：2010-12-15

申请号：EP02764577.9

申请日：2002-06-04

Applicant: BASF SE

Inventor： NESVADBA, Peter ,  HINTERMANN, Tobias ,  KRAMER, Andreas ,  ZINK, Marie-Odile ,  BUGNON, Lucienne

IPC: C07D211/94 ,  C08F4/00

CPC classification number: C07D211/94

Abstract: The present invention relates to selected 4-imino-N-alkoxy-polyalkyl-peperidine compounds preparation, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) a 4-imino-N-alkoxy-polyalkyl-piperidine compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers, and the use of 4-imino-N-alkoxy-polyalkyl-piperidine compounds for controlled polymerization. The intermediate N-oxyl derivatives, a composition of the N-oxyl derivatives with ethylenically unsaturated monomers and a free radical initiator, as well as a process for polymerization are also subjects of the present invention.

公开(公告)号：EP2162937A1

公开(公告)日：2010-03-17

申请号：EP08760707.3

申请日：2008-06-09

Applicant: BASF SE

Inventor： NESVADBA, Peter ,  BUGNON FOLGER, Lucienne ,  HINTERMANN, Tobias

IPC: H01M4/60 ,  H01M10/40 ,  H01M4/02

CPC classification number: H01M4/60 ,  H01M4/13 ,  H01M4/364 ,  H01M4/602 ,  H01M4/608 ,  H01M10/05 ,  H01M10/052

Abstract: This invention relates to a stable secondary battery utilizing as active principle the oxidation and reduction cycle of a sterically hindered nitroxide radical, a sterically hindered oxoammoinum cation, a sterically hindered hydroxylamine or a sterically hindered aminoxide anion containing a piperazin-2,6-dione, a piperazin-2-one or morpholin-2-one structural unit. Further aspects of the invention are a method for providing such a secondary battery, the use of the respective compounds as active elements in secondary batteries and selected novel compounds.